Vitamin D and neuralgia in multiple myeloma

Vitamin D status and peripheral neuropathy in multiple myeloma patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON27690

Enrollment

120

Registered

2016-07-28

Start date

2016-09-26

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral neuropathy - perifere neuropathie Multiple myeloma - multipel myeloom Vitamin D - vitamine D

Interventions

- Blood samples will be drawn to determine 25-hydroxyvitamin D levels. - All patients will complete the self-assessment survey ICPNQ and when necessary the VAS score, to distinguish different PN grad

Eligibility

Inclusion criteria

Inclusion criteria: Patients with smoldering or symptomatic multiple myeloma Patients 18 years or older Able to give informed consent

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
The correlation between PN and the vitamin D status in MM patients.	—

Secondary

Measure	Time frame
- to evaluate the influence of vitamin D on the severity of PN - to determine the correspondence of the ICPNQ results and patients’ records. - the number of patients with low 25-hydroxyvitamin D serum levels - to search for differences in incidence of PN for each drug	—

Contacts

Public ContactBerdien Oortgiesen

Medisch Centrum Leeuwarden

Berdien.Oortgiesen@znb.nlTel: 058- 286 1918

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)